CSL Ausschüttungen und Rückkäufe
Zukünftiges Wachstum Kriterienprüfungen 3/6
CSL ist ein dividendenzahlendes Unternehmen mit einer aktuellen Rendite von 2.27%. Das nächste Zahlungsdatum ist am 2nd October, 2026 mit einem Ex-Dividendendatum von 9th September, 2026.
Wichtige Informationen
2.3%
Dividendenausschüttung
1.1%
Rückkaufsrendite
| Gesamte Aktionärsrendite | 3.4% |
| Zukünftige Dividendenrendite | 2.7% |
| Wachstum der Dividende | 8.0% |
| Nächster Dividendenzahlungstermin | 02 Oct 26 |
| Ex-Dividendendatum | 09 Sep 26 |
| Dividende pro Aktie | n/a |
| Ausschüttungsquote | -55% |
Jüngste Updates zu Dividenden und Rückkäufen
Recent updates
Narrative-Update • Sep 17
CSL: Vaccine And Pipeline Progress Will Support Future Rebound Case
Analysts have lifted the CSL fair value estimate by about A$21 to A$209.24, reflecting updated assumptions for earnings growth, profit margins and an "undemanding" valuation that has supported a higher price target for the stock. Analyst Commentary on CSL Recent commentary on CSL points to a more constructive tone among bullish analysts.
Narrative-Update • Sep 03
CSL: Rooftop Cost Inflation And New Capacity Will Pressure Future Returns
Analysts have lifted the CSL fair value estimate from A$107.97 to A$132.73, reflecting updated assumptions for a slightly lower discount rate, more modest revenue growth, a higher profit margin profile, and a higher future P/E multiple informed by recent research on roofing demand, input cost pressures, and potential acquisition activity in the sector. Analyst Commentary Recent Street research around Carlisle Companies, or CSL, shows a mixed tone, with some firms expressing confidence in roofing demand and others highlighting risks around costs, competitive capacity, and potential acquisition activity.
Narrative-Update • Aug 20
CSL: Roofing Restructuring And Owens Corning Optionality Will Shape Earnings Path
Analysts have lifted their fair value estimate for Carlisle (CSL) to A$163.95 from A$138.19, reflecting updated assumptions on the discount rate, slightly higher profit margins and a higher future P/E multiple. They are also factoring in recent research that adjusts expectations around roofing demand, input costs and potential Owens Corning deal scenarios.Narrative-Update • Aug 17
CSL: Higher Assumed Profitability Will Support Future Rebound Case
Analysts have trimmed their CSL price target by about A$8 to reflect a slightly higher discount rate, while also factoring in marginally stronger long term revenue growth, profit margins and a modestly lower future P/E multiple. Valuation Changes for CSL Fair Value has moved from A$196.66 to A$188.25, which is a small reduction in the modelled valuation for CSL shares.Narrative-Update • Aug 06
CSL: Roofing Cost Inflation And New Capacity Will Drive Tougher Repricing
Analysts have lifted their fair value estimate for Carlisle Companies (CSL) by about A$4 to roughly A$108 per share, citing updated assumptions on revenue growth, profit margins, and future P/E following recent price target revisions across the stock and related roofing peers. Analyst Commentary Recent research on Carlisle Companies highlights a mix of optimism about the stock's long term positioning alongside pockets of caution around execution, valuation, and industry headwinds.Narrative-Update • Jul 23
CSL: Cost Pressures And Margin Strain Will Drive A Tougher Repricing Phase
Analysts have reduced their price target on CSL to A$103.54 from A$180.87, citing updated assumptions for the discount rate, profit margin and future P/E in light of recent sector research and mixed signals around roofing demand and input costs. Analyst Commentary Recent Street research around Carlisle Companies, or CSL, reflects a more cautious tone as roofing demand signals remain mixed and cost pressures stay in focus.Narrative-Update • Jul 09
CSL: Roofing Platform Repricing Will Drive Future Rebound Case
Analysts have reduced their price target on CSL to about A$196.66 from about A$289.37, citing updated assumptions around discount rates, profit margins, and future P/E expectations. Analyst Commentary Recent research around CSL highlights a split in views, with some cautious adjustments to assumptions and at least one downgrade, while other coverage of the broader roofing sector points to potential catalysts that investors may still weigh when assessing CSL.
Neues Narrative • Jun 28
Strong buy. World-leading healthcare company with steady growth
CSL is one of Australia’s highest-quality businesses and has a long history of delivering strong returns. It is a global leader in plasma therapies, vaccines and biotechnology, with products that are difficult to replicate and protected by strict regulation.Narrative-Update • Jun 25
CSL: Cost Cuts And Capacity Expansion Will Support Long Term Earnings Recovery
Analysts have trimmed their price target on CSL to about A$138 from roughly A$141. This reflects a slightly higher discount rate, modestly adjusted revenue growth and profit margin assumptions, and a lower future P/E multiple in their updated valuation work.Analyseartikel • Jun 16
CSL (ASX:CSL) Shares Could Be 31.5% Undervalued Before Full Year Results
CSL (ASX:CSL) is back in focus after a sharp share price rebound, with investors weighing the upcoming August 18 full-year results and dividend announcement against recent guidance cuts and asset impairments. See our latest analysis for CSL. The recent rebound has lifted CSL’s 7 day share price return to 6.8% and its 30 day share price return to 8.5%. However, its year to date share price return is still down 38.2% and the 1 year total shareholder return has declined 54.5%. This indicates...Narrative-Update • Jun 11
CSL: Cost Transformation And Capacity Expansion Will Support Long Term Earnings Power
Narrative Update on CSL The analyst fair value estimate for CSL has been revised from A$146.21 to A$140.86, with analysts citing updated assumptions for revenue growth, profit margins and forward P/E multiples in light of recent sector and company specific research. Analyst Commentary Recent research on CSL has pointed to a mix of optimism and caution, with valuation assumptions and execution risks front and center.
Neues Narrative • Jun 10
CSL Investment Thesis
CSL Limited Australian Securities Exchange · ASX: CSL · Plasma therapeutics, vaccines, nephrology RECOMMENDATION: DEFER INITIATION — do not deploy capital before the 18 August 2026 FY26 result. The thesis hinges on a single variable — whether the core Behring franchise is derating permanently or cyclically — which resolves on a known date roughly ten weeks out.Narrative-Update • May 27
CSL: U.S. Capacity Expansion Will Support Long Term Earnings Power
Analysts have revised CSL's fair value estimate down from A$195.41 to A$146.21. This reflects updated views on slightly higher discount rates, more moderate revenue growth, softer profit margins and a lower assumed future P/E multiple.Narrative-Update • May 09
CSL: U.S. Manufacturing Expansion And CEO Transition Will Support Long Term Upside
CSL's analyst price target has been adjusted slightly lower to A$195.41 from A$198.79 as analysts factor in marginally softer revenue growth, a small reduction in projected profit margins, a slightly lower discount rate, and a modestly lower future P/E assumption. Analyst Commentary Recent Street research on the sector, including coverage of CSL peers, points to a mix of optimism about execution and long term growth, alongside pockets of caution on valuation and macro sensitivity.Narrative-Update • Apr 22
CSL: Manufacturing Expansion And CEO Transition Will Support Long Term Share Rebound
The CSL analyst price target has been trimmed by about A$9, as analysts now factor in slightly lower revenue growth, a modestly softer profit margin outlook, a marginally higher discount rate and a small reset in assumed future P/E multiples. Analyst Commentary Recent Street research on CSL and peers points to a mixed but useful read on how analysts are thinking about valuation, execution risk and growth expectations.Narrative-Update • Apr 08
CSL: Manufacturing Expansion And CEO Transition Will Support Future Share Recovery
Analysts have slightly increased CSL's fair value estimate to A$208.11, citing modest adjustments to the discount rate, revenue growth, profit margin and a higher assumed future P/E multiple as they reassess the stock following recent rating changes. Analyst Commentary Recent rating actions around CSL highlight a split in views on how much investors should pay for the stock at this stage, which feeds directly into the updated fair value estimate of A$208.11.Narrative-Update • Mar 25
CSL: Manufacturing Expansion And Horizon 2 Rollout Will Support Future Share Recovery
Narrative Update on CSL Analysts have adjusted CSL's fair value estimate from A$205.16 to A$207.81. This reflects updated views on its discount rate, revenue growth, profit margins and future P/E assumptions, alongside recent mixed rating actions on the stock.Narrative-Update • Mar 10
CSL: Manufacturing Expansion And Leadership Transition Will Support Future Share Recovery
Analysts have trimmed their CSL price target by about A$6 to reflect slightly lower long term fair value estimates, modestly higher discount rates and more conservative assumptions for revenue growth and profit margins, partially offset by a higher future P/E multiple. Analyst Commentary Recent Street research around CSL points to a mixed setup, with some firms taking a more constructive stance and others turning cautious.Neues Narrative • Mar 09
CSL: The Dip Is the Opportunity
CSL: The Dip Is the Opportunity Most people look at CSL's stock chart right now and see a problem. Down 35% from its highs, margins cut in half, and a company in the middle of its biggest restructuring in decades.Narrative-Update • Feb 24
CSL: Execution On Gene Therapy And Leadership Transition Will Support Share Recovery
Analysts have trimmed their CSL fair value estimate to A$210.90 from A$228.58 as updated assumptions on discount rate, revenue growth, profit margins and future P/E feed through into a lower overall price target. Analyst Commentary Recent research views on CSL have been mixed, with some analysts turning more cautious while others have taken a more constructive stance at different points.Neues Narrative • Feb 22
My view on CSL Limited is positive. It’s a high-quality growth stock with strong barriers to entry through its global plasma network.
One stock I find particularly compelling is CSL Limited (ASX: CSL), primarily due to its strong competitive positioning, structural growth drivers, and valuation complexity. From a fundamental perspective, CSL operates in the global plasma therapies and specialty pharmaceuticals market, where demand is relatively inelastic and supported by long-term healthcare trends.Analyseartikel • Feb 17
CSL's (ASX:CSL) Soft Earnings Are Actually Better Than They Appear
Investors were disappointed with the weak earnings posted by CSL Limited ( ASX:CSL ). While the headline numbers were...Narrative-Update • Feb 10
CSL: Share Recovery Will Be Supported By Execution And Recent Upgrade
Analysts have trimmed their fair value estimate for CSL to about A$228.58 from A$232.54, reflecting updated assumptions around discount rates, revenue growth, profit margins and future P/E expectations. Analyst Commentary Recent Street research on CSL points to a mix of optimism and caution, which helps explain the modest trim in fair value.Neues Narrative • Feb 07
Seqirus Demerger And Cost Savings Will Shape A Steady Long Term Outlook
Catalysts About CSL CSL is a global biopharmaceutical group focused on plasma therapies, vaccines and specialty medicines addressing rare and serious diseases. What are the underlying business or industry changes driving this perspective?Narrative-Update • Jan 26
CSL: Share Recovery Will Be Driven By Seqirus Reset And Demerger Deferral
Analysts have raised their fair value target for CSL to A$232.54. This reflects slightly adjusted assumptions for revenue growth, profit margins and future P/E multiples after recent upgrades and renewed interest in the shares.Narrative-Update • Jan 11
CSL: Shares Will Recover As Seqirus Reset And Demerger Deferral Settle
Analysts have trimmed their CSL price target slightly, with fair value moving from about A$236.57 to A$232.45, as they factor in softer Seqirus vaccination trends and the deferred vaccine demerger, while still seeing the recent share pullback as an opportunity to re-engage with the stock. Analyst Commentary Recent research on CSL focuses heavily on the updated outlook for Seqirus, the indefinitely deferred vaccine demerger, and where the current share price sits relative to revised fair value estimates.Narrative-Update • Dec 17
CSL: Shares Will Recover As Seqirus Drag Fades After AGM Downgrade
Analysts have nudged down their price target on CSL by A$5 to reflect slightly softer long term revenue growth assumptions and a modestly higher discount rate, even as they highlight resilient margins and view the recent selloff as an opportunity to re engage with the shares. Analyst Commentary Recent commentary around CSL reflects a more constructive stance on the stock despite near term earnings noise, with valuation support emerging after the sharp pullback.Narrative-Update • Dec 03
CSL: Shares Will Recover As Seqirus Headwinds Ease After Recent Pullback
Analysts have trimmed their price target on CSL slightly, from about A$230 to A$225, reflecting tempered expectations for Seqirus amid weaker U.S. vaccination trends and the indefinite deferral of the planned vaccine business demerger, even as they note that the recent share price correction has opened a more attractive entry point. Analyst Commentary Analyst views on CSL have turned more constructive following the share price pullback, even as earnings expectations have been nudged lower to reflect the softer outlook for Seqirus.Narrative-Update • Nov 19
CSL: Share Price Will Rebound After Vaccine Demerger Deferral And Segment Headwinds
Analysts have marginally increased their fair value estimate for CSL from $246.49 to $246.96. This reflects a cautiously optimistic outlook as concerns over segment performance and revised vaccination forecasts are balanced by expectations of a market overreaction and longer-term recovery potential.Narrative-Update • Nov 04
CSL: Share Price Correction Will Present Opportunity As Vaccine Uncertainty Eases
CSL's analyst price target has been lowered from A$280.61 to A$246.49, reflecting analysts' revised expectations following recent updates about weaker revenue growth, a more cautious profit margin outlook, and continued challenges in key business units. Analyst Commentary Market analysts have offered mixed perspectives on CSL following recent trading updates and management commentary, resulting in shifts in both ratings and price targets.Narrative-Update • Oct 21
Analysts Adjust CSL Outlook as Valuation Rises Amid Mixed Market Sentiment and Company Updates
CSL's fair value estimate has increased modestly by $0.23 to $280.61, as analysts factor in softened revenue and profit margin assumptions in light of near-term challenges in end-market demand and distributor activity. Analyst Commentary Recent street research reflects both cautious and optimistic views toward CSL's near-term execution and longer-term prospects.Narrative-Update • Oct 03
Operational Improvements Will Unlock Biotech Potential And China Market Expansion
The analyst consensus price target for CSL has been revised downward by 1.5% to $280.38. Analysts cite near-term uncertainties in end-market demand and distribution dynamics as key factors in the updated valuation.Analyseartikel • Sep 25
CSL Limited's (ASX:CSL) Share Price Not Quite Adding Up
With a median price-to-earnings (or "P/E") ratio of close to 21x in Australia, you could be forgiven for feeling...Narrative-Update • Sep 04
Operational Improvements Will Unlock Biotech Potential And China Market Expansion
Despite the consensus Analyst Price Target for CSL remaining largely unchanged, the significant increase in Future P/E from 26.27x to 40.16x indicates investor expectations for higher earnings growth or a premium valuation, resulting in only a marginal fair value decrease to A$284.79. What's in the News CSL plans to demerge its influenza vaccine division, CSL Seqirus, into a separately listed company by end of FY26, along with job cuts and a share repurchase program to allow strategic autonomy.Narrative-Update • Aug 20
Advancements In iNOMi Technology And HEMGENIX Will Strengthen Market Position
CSL's consensus price target has been revised downward, reflecting a material drop in expected revenue growth alongside a sharply higher future P/E ratio, with fair value now set at A$291.99. What's in the News CSL expects group revenue growth of approximately 4-5% and NPATA growth of 7-10% for FY26, excluding non-recurring restructuring costs.Neues Narrative • Apr 15
CSL is undervalued in High Tax Scenario
CSL Behring: This is CSL's largest segment and the global leader (#1) in plasma therapies within an estimated US$30 billion industry.11 It focuses on researching, developing, manufacturing, and distri
Neues Narrative • Feb 23
Advancements In iNOMi Technology And HEMGENIX Will Strengthen Market Position
Advancements in plasma collection and operational efficiencies are set to reduce costs and improve CSL Behring's margins, potentially boosting overall earnings.Stabilität und Wachstum des Zahlungsverkehrs
Rufe Dividendendaten ab
Stabile Dividende: CSLDie Dividende je Aktie war in den letzten 10 Jahren stabil.
Wachsende Dividende: CSLDie Dividendenzahlungen des Unternehmens sind in den letzten 10 Jahren gestiegen.
Dividendenrendite im Vergleich zum Markt
| CSL Dividendenrendite im Vergleich zum Markt |
|---|
| Segment | Dividendenrendite |
|---|---|
| Unternehmen (CSL) | 2.3% |
| Untere 25 % des Marktes (AU) | 2.8% |
| Markt Top 25 % (AU) | 6.3% |
| Branchendurchschnitt (Biotechs) | 1.9% |
| Analystenprognose (CSL) (bis zu 3 Jahre) | 2.7% |
Bemerkenswerte Dividende: CSLDie Dividende des Unternehmens (2.27%) ist im Vergleich zu den unteren 25 % der Dividendenzahler auf dem Markt Australian (2.75%) nicht bemerkenswert.
Hohe Dividende: CSLDie Dividende des Unternehmens (2.27%) ist im Vergleich zu den besten 25% der Dividendenzahler auf dem Markt Australian (6.33%) niedrig.
Gewinnausschüttung an die Aktionäre
Abdeckung der Erträge: CSL zahlt eine Dividende, aber das Unternehmen ist unrentabel.
Barausschüttung an die Aktionäre
Cashflow-Deckung: Mit einer angemessenen Ausschüttungsquote (62.6%) sind die Dividendenzahlungen von CSL durch den Cashflow gedeckt.
Entdecken Sie dividendenstarke Unternehmen
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/09/22 08:39 |
| Aktienkurs zum Tagesende | 2026/09/22 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2026/06/30 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
CSL Limited wird von 26 Analysten beobachtet. 17 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Saul Hadassin | Barrenjoey Markets Pty Limited |
| Thomas Wakim | Bell Potter |
| Lyanne Harrison | BofA Global Research |